一项多中心、前瞻性、盲法、非选择研究评估基于靶向二代测序的胚胎植入前非整倍体遗传学检测非整倍体诊断的预测价值及活检的影响
该多中心前瞻性盲法非选择研究纳入402例首次体外受精且无复发性流产、窦卵泡计数<8或体重指数≥35 kg/m²的夫妇,对484枚单囊胚冻融移植在临床结局确定后行靶向二代测序PGT-A,非整倍体诊断临床错误率为0%,滋养层活检对持续种植无不良影响(研究组47.9% vs 年龄匹配对照组45.8%)。
要点
- 非整倍体诊断临床错误率为0%,对未成功分娩具有高度预测性。
- 滋养层活检对持续种植无不良影响(47.9% vs 45.8%)。
- 研究设计为前瞻性、盲法、多中心、非选择研究。
核心结论
- 所评估的PGT-A检测在获得非整倍体结果时对未成功分娩具有高度预测性。
- 滋养层活检未检测到对持续种植的不良影响。
研究设计与样本
- 前瞻性、盲法、多中心、非选择研究,纳入402例患者,共484枚单囊胚冻融移植。
- 所有可用囊胚均活检,在遗传分析前移植形态学最佳的单个囊胚,临床结局确定后行PGT-A检测。
- 患者为首次体外受精周期且无复发性流产、窦卵泡计数<8或体重指数≥35 kg/m²的夫妇。
- 干预:无。
主要发现
- PGT-A非整倍体诊断的临床错误率为0%。
- 研究组与年龄匹配未活检对照组的持续种植率无差异(47.9% vs 45.8%)。
关键数值与推荐
- 主要结局为非整倍体分析结果预测未成功分娩(临床结果)的能力。
- 次要结局为滋养层活检对持续种植的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the predictive value of an aneuploid diagnosis with a targeted next-generation sequencing-based preimplantation genetic testing for aneuploidy (PGT-A) assay in prognosticating the failure of a successful delivery. DESIGN: Prospective, blinded, multicenter, nonselection study. All usable blastocysts were biopsied, and the single best morphologic blastocyst was transferred before genetic analysis. Preimplantation genetic testing for aneuploidy was performed after clinical outcome was determined. Clinical outcomes were compared to PGT-A results to calculate the predictive value of a PGT-A aneuploid diagnosis. SETTING: Fertility centers. PATIENT(S): Couples undergoing their first in vitro fertilization cycle without recurrent pregnancy loss, antral follicle count < 8, or body mass index ≥ 35 kg/m2. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The primary outcome was the ability of the analytical result of aneuploid to predict failure to deliver (clinical result). A secondary outcome was the impact of the trophectoderm biopsy on sustained implantation. RESULT(S): Four hundred two patients underwent 484 single, frozen, blastocyst transfers. The PGT-A aneuploid diagnosis clinical error rate was 0%. There was no difference in sustained implantation between the study group and an age-matched control group, where biopsy was not performed (47.9% vs. 45.8). CONCLUSION(S): The PGT-A assay evaluated was highly prognostic of failure to deliver when an aneuploid result was obtained. Additionally, the trophectoderm biopsy had no detectable adverse impact on sustained implantation. CLINICAL TRIAL REGISTRATION NUMBERS: NCT02032264 and NCT03604107.
引用
- Tiegs AW, Tao X, Zhan Y, et al. A multicenter, prospective, blinded, nonselection study evaluating the predictive value of an aneuploid diagnosis using a targeted next-generation sequencing-based preimplantation genetic testing for aneuploidy assay and impact of biopsy. Fertil Steril. 2020. PMID: 32863013. doi:10.1016/j.fertnstert.2020.07.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。